Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
Conditions
Keywords
Vomiting, CINV, Emesis, Nausea, Chemotherapy-Induced Nausea and Vomiting
Brief summary
This study was designed to assess the safety and efficacy of different dosages and administration schedules of an investigational agent administered over 3 days when added to standard therapy used in the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Subjects will be asked to complete daily diaries while on study medication. In addition subjects will be required to return to the investigational site several times during the course of the study for follow up safety assessments which may include blood samples for hematology and chemistry evaluations as well as physical exams. A final assessment will be preformed on study Day 20-30 at which time the subject will complete the study.
Detailed description
A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study of the Safety and Efficacy of the Oral NeuroKinin-1 Receptor Antagonist, GW679769 in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Moderately Emetogenic Chemotherapy
Interventions
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Willing to provide a written informed consent prior to receiving any study-specific procedures or assessments. * Diagnosed with a solid malignant tumor and has not previously received chemotherapy. * Scheduled to receive chemotherapy conducive to regimens outlined in the study protocol.
Exclusion criteria
* Not received any investigational product within 30 days of enrollment into the study. * Must not be pregnant. * Must not be of childbearing potential or is willing to use specific barrier methods outlined in the protocol. * Must not be scheduled to receive radiation therapy to the abdomen or to the pelvis within seven (7) days prior to starting study medication. * Must not be currently under treatment for a condition which may cause nausea or vomiting (i.e., active peptic ulcer disease, gastric obstruction). * Must not have a history of peptic ulcer disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Based on the number of subjects who do not experience vomiting, retching or nausea over a 5 day period following the initiation of chemotherapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Based on routine physical exam findings, vital signs, routine clinical laboratory tests, clinical monitoring and/or observation, and adverse events reporting performed during scheduled visits. | — |
Countries
Argentina, Austria, Canada, Chile, Croatia, Czechia, Germany, Greece, Hong Kong, Hungary, Ireland, Mexico, Pakistan, Philippines, Poland, Portugal, Russia, Singapore, Slovakia, Spain, Taiwan, Thailand, United Kingdom, United States
Outcome results
None listed